Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.54 |
| ▸ | FLT1 | P17948 | 9/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540171 | 0.95 | ABL1 (0.58) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3535806 | 0.94 | ABL1 (0.72) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3534492 | 0.92 | ABL1 (0.75) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL5866633 | 0.91 | ABL1 (0.77) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3534965 | 0.89 | ABL1 (0.68) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3535472 | 0.89 | ABL1 (0.67) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3535846 | 0.89 | ABL1 (0.66) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3538447 | 0.88 | FGFR1 (0.69) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3543324 | 0.88 | ABL1 (0.68) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL3539015 | 0.88 | FGFR1 (0.55) | ABL1FGFR1FLT1KDRBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858792-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090176767-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20060205949-A1 | Crystalline forms of a biphenyl compound | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205949-A1 | Crystalline forms of a biphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6, SULT2A1 | ABL1 1065/4885FGFR1 15/4885FLT1 1390/4885 |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ABL1 3323/4885FGFR1 724/4885FLT1 914/4885 |
| US-20090176767-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | ABL1 3323/4885FGFR1 724/4885FLT1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.